Design and Evaluation of Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory Process That Preserves Immune Cell Viability.
Ladi, E., Everett, C., Stivala, C.E., Daniels, B.E., Durk, M.R., Harris, S.F., Huestis, M.P., Purkey, H.E., Staben, S.T., Augustin, M., Blaesse, M., Steinbacher, S., Eidenschenk, C., Pappu, R., Siu, M.(2019) J Med Chem 62: 7032-7041
- PubMed: 31283222 
- DOI: 10.1021/acs.jmedchem.9b00509
- Primary Citation of Related Structures:  
6E5B - PubMed Abstract: 
The pan-proteasome inhibitor bortezomib demonstrated clinical efficacy in off-label trials of Systemic Lupus Erythematosus. One potential mechanism of this clinical benefit is from the depletion of pathogenic immune cells (plasmablasts and plasmacytoid dendritic cells) ...